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Objectives: Dry eye disease (DED) is an increasingly important public health problem in Korea. Previous studies conducted in Korea 
have reported inconsistent results regarding the protective effects of vitamin D on DED, and these discrepancies may be related to the 
relatively simple questionnaire that has been used. Thus, we evaluated the association of serum vitamin D levels with DED using the 
ocular surface disease index (OSDI). 
Methods: The present study evaluated data from participants in the Study Group for Environmental Eye Disease (2014-2015). This 
group included data from 752 participants, and data from 740 participants (253 men and 487 women) were analyzed in the present 
study. DED severity was evaluated using the OSDI. 
Results: Higher serum vitamin D levels were associated with a non-significantly reduced risk of DED in the crude analysis (odds ratio 
[OR], 0.991; 95% confidence interval [CI], 0.971 to 1.011) and in the adjusted analysis (OR, 0.988; 95% CI, 0.966 to 1.010). In the crude 
analysis of no/mild DED vs. moderate/severe DED, men exhibited a decreased risk with increasing serum vitamin D levels (OR, 0.999; 
95% CI, 0.950 to 1.051), while women exhibited an increased risk (OR, 1.003; 95% CI, 0.979 to 1.027). In these analyses, we found no 
significant associations.
Conclusions: The findings of the present study support previous reports that serum vitamin D levels are not associated with DED. 
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INTRODUCTION
Dry eye disease (DED) is a tear film disorder caused by 
chronic inflammation of the lacrimal functional unit [1]. DED is 
one of the most common complaints of patients who visit an 
ophthalmologist, and most patients with this condition expe-
rience symptoms including ocular discomfort, pruritus, red-
ness, pain, and eye fatigue [1-3]. DED is also becoming an in-
creasingly important public health problem because it affects 
vision-related quality of life (e.g., through adverse effects on 
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reading and driving ability) [2-4]. Moreover, the prevalence of 
DED is increasing worldwide, and its prevalence is higher 
among Asian populations than among Western populations 
[5-10]. A Korean study reported that the prevalence of DED 
was 8.0% based on physician diagnoses and 14.4% based on 
DED symptoms [11].
Recent studies have suggested that vitamin D can protect 
against DED [12-15]. Vitamin D is a fat-soluble vitamin that is 
produced by cutaneous synthesis after sun exposure [16], and 
it has well-known musculoskeletal functions in the cartilage 
and bone [17,18]. Vitamin D has also been reported to have 
protective effects against various health problems, such as 
cardiovascular disease (CVD), diabetes, malignancies [19-22], 
and some eye disorders [23,24]. Some Korean studies have 
evaluated the associations of serum vitamin D levels with DED 
using Korea National Health and Nutrition Examination Survey 
(KNHANES) data, but their results were inconsistent [25-27]. 
They used a simple questionnaire about dry eye syndromes 
[28]. Therefore, we investigated the association between se-
rum vitamin D levels and DED among Korean adults based on 
the ocular surface disease index (OSDI).
METHODS
The present study evaluated data from the Study Group for 
Environmental Eye Disease (SEED). The SEED study is an ancil-
lary study of the Cardiovascular and Metabolic Disease Etiolo-
gy Research Center (CMERC) cohort. The CMERC study is an 
ongoing cohort study (started in 2013) investigating risk fac-
tors for CVD and metabolic disease among the general popu-
lation of healthy community-dwelling Korean adults (≥30 
years old) [29]. The SEED study is an ongoing multidisciplinary 
study (started in 2013) that evaluates diagnostic and thera-
peutic biomarkers for environmental eye diseases. The present 
study analyzed data that were collected during 2014-2015 
from the SEED study (752 participants), although we excluded 
12 participants because they had missing data for relevant 
variables. Thus, we analyzed data from 740 participants (253 
men and 487 women). The protocol of the present study was 
approved by the institutional review board of Severance Hos-
pital (Yonsei University College of Medicine). All participants 
provided informed consent before participating in the CMERC 
and SEED studies. 
In the present study, DED was defined as an OSDI score of 
≥13.0. The OSDI uses a DED-specific questionnaire that was 
developed by the Outcomes Research Group at Allergan, and 
consists of questions regarding vision-related function (4 
questions), eye symptoms (5 questions), and environmental 
triggers related to DED (3 questions). Each question is scored 
from 0 to 4, and the total OSDI score is calculated using the 
following formula: OSDI= ([sum of scores for all questions an-
swered]×100) / ([total number of questions answered]×4), 
with results on a scale of 0 to 100. No DED (i.e., normal status) 
is defined as an OSDI score of <13.0. The severity of DED is de-
fined as mild (scores of 13.0-22.9), moderate (23.0-32.9), and 
severe (scores of 33.0-100.0). Previous studies have confirmed 
that the OSDI is a valid and reliable tool for measuring DED 
symptoms and their effects on vision-related quality of life 
[30,31]. Trained interviewers individually administered the 
questionnaires to collect data regarding the participants’ de-
mographic information, medical history, and OSDI.
Serum vitamin D levels (25-hydroxyvitamin D) were as-
sessed using a chemiluminescence immunoassay  (Liason, Dia-
Sorin, Saluggia, Italy). Peripheral blood samples were obtained 
after an overnight fast, and all bioassays were performed at a 
central laboratory (Seoul Clinical Laboratories R&D Center, 
Seoul, Korea). Concentrations of blood glucose were measured 
using a colorimetric analyzer, while lipid profiles (including to-
tal cholesterol and high-density lipoprotein [HDL] cholesterol) 
were analyzed enzymatically. Glycated hemoglobin (HbA1c) 
concentrations were measured using high-performance liquid 
chromatography. Height was measured using a stadiometer 
(DS-102; Jenix, Seoul, Korea), and body weight was measured 
using a digital scale (DB-150; CAS, Seongnam, Korea). Body 
mass index (BMI) was calculated as body weight divided by 
height squared (kg/m2). Systolic and diastolic blood pressures 
were measured 3 times in the right arm, and the average val-
ues of the second and third measurements were used for the 
analysis [29].
Previous studies have revealed that the major risk factors or 
confounders for DED include age, women, BMI, smoking, his-
tory of eye surgery, diabetes mellitus, visual display terminal 
(VDT) use, contact lens use, and education level [10,32,33]. 
Thus, when available, we included these variables in our mul-
tivariate analyses. Diabetes mellitus was defined as a fasting 
blood glucose concentration of ≥126 mg/dL, an HbA1c con-
centration of ≥6.5%, or the current use of oral medication or 
insulin injection. Participants were classified according to 
smoking status as never smokers, former smokers, or current 
smokers. Because the effect sizes varied according to gender, 
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we performed analyses of all participants together and of men 
and women separately. Continuous and normally distributed 
variables were compared using the t-test, and non-normally 
distributed continuous variables were compared using the 
Wilcoxon rank-sum test. Categorical variables were compared 
using the chi-square test. All tests were 2-tailed, and differenc-
es were considered statistically significant at p-values of 
<0.05. The associations of serum vitamin D levels with DED 
were evaluated using logistic regression analyses. Model 1 was 
not adjusted for any variables, model 2 was adjusted for age 
and BMI, and model 3 was adjusted for age, BMI, systolic/dia-
stolic blood pressure, total cholesterol, HDL cholesterol, fast-
ing glucose concentration, contact lens use, VDT use, history 
of eye surgery, and education level. The results of the logistic 
regression analyses were reported as odds ratios (ORs) with 
95% confidence intervals (CIs). All analyses were performed 
using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Table 1 shows the participants’ characteristics. As defined by 
an OSDI score of ≥13.0, the prevalence of DED among the 
740 participants was 53.1%. The prevalence of DED among 
women was significantly higher than among men (58.7 vs. 
42.3%, respectively; p<0.01). The median age was 53.0 years 
(51.0 years for men and 54.0 years for women). The univariate 
analyses revealed significant gender-related differences in the 
values for serum vitamin D, age, BMI, systolic blood pressure, 
diastolic blood pressure, HDL cholesterol, triglycerides, fasting 
glucose, history of hypertension, VDT use for >4 hours, smok-
Table 1. General characteristics of the participants according to gender
Variables Total (n =  740) Men (n =  253) Women (n =  487) p-value
OSDI score 14.6 [6.3, 27.1] 10.7 [4.2, 20.8] 16.7 [8.3, 29.5] <0.01
Age (y) 53.0 [42.0, 58.0] 51.0 [39.0, 58.0] 54.0 [45.0, 58.0] 0.05
Triglycerides (mg/dL) 107.5 [79.0, 155.0] 132.0 [95.0, 186.0] 98.0 [73.0, 134.0] <0.01
Fasting glucose (mg/dL) 88.0 [82.0, 95.0] 90.0 [84.0, 99.0] 87.0 [81.0, 93.0] <0.01
HbA1c (%) 5.6 [5.4, 5.9] 5.6 [5.4, 5.9] 5.6 [5.3, 5.9] 0.40 
Serum vitamin D (ng/mL) 13.5 [10.4, 18.6] 14.3 [10.9, 18.5] 13.1 [10.0, 18.6] 0.03
Body mass index (kg/m2) 23.6±3.1 24.6±3.0 23.1±3.0 <0.01
Systolic blood pressure (mmHg) 117.9±14.6 125.0±12.8 114.3±14.2 <0.01
Diastolic blood pressure (mmHg) 74.8±9.5 79.8±9.3 72.2±8.5 <0.01
Total cholesterol (mg/dL) 197.9±34.7 195.8±34.9 199.0±34.6 0.24
HDL cholesterol (mg/dL) 57.9±14.7 51.1±12.4 61.4±14.6 <0.01
Diabetes 72 (9.7) 29 (11.5) 43 (8.8) 0.31
Hypertension 163 (22.0) 78 (30.8) 85 (17.5) <0.01
Contact lens use 20 (2.7) 6 (2.4) 14 (2.9) 0.81
History of eye surgery 103 (13.9) 35 (13.6) 68 (13.8)
VDT use (>4 hr) 198 (26.8) 112 (44.3) 86 (17.7) <0.01
Smoking status (%) <0.01
Never smoker 512 (69.2) 63 (24.9) 449 (92.2)
Former smoker 127 (17.2) 103 (40.7) 24 (4.9)
Current smoker 101 (13.6) 87 (34.4) 14 (2.9)
Education level <0.01
≤High-school graduate 379 (51.2) 92 (36.4) 287 (58.9)
>High-school graduate 361 (48. 8) 161 (63.6) 200 (41.1)
Severity of DED (OSDI score) <0.01
No DED (<13.0) 347 (46.9) 146 (57.7) 201 (41.3)
Mild DED (13.0-22.9) 169 (22.8) 57 (22.5) 112 (23.0)
Moderate DED (23.0-32.9) 93 (12.6) 22 (8.7) 71 (14.6)
Severe DED (33.0-100.0) 131 (17.7) 28 (11.1) 103 (21.1)
Values are presented as mean±standard deviation, median [interquartile range], or number (%).
OSDI, ocular surface disease index; HbA1C, glycosylated hemoglobin; HDL, high-density lipoprotein; VDT, visual display terminal; DED, dry eye disease. 
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ing status, and education level. No gender-related differences 
were observed in the values for total cholesterol, HbA1c, his-
tory of diabetes mellitus, or contact lens use.
The participants’ characteristics according to DED status are 
shown in Table 2. Serum vitamin D levels were slightly higher 
among individuals without DED than among individuals with 
DED, and this non-significant association was observed among 
all participants (p=0.10), among men (p=0.74), and among 
women (p=0.35). The only significant differences in the over-
all analyses were observed in the values for systolic blood 
pressure, diastolic blood pressure, and HDL cholesterol among 
all participants. 
Higher serum vitamin D levels were associated with a non-
significant reduction in the risk of DED in the crude analysis 
(OR, 0.991; 95% CI, 0.971 to 1.011) and in the fully adjusted 
analysis (OR, 0.988; 95% CI, 0.967 to 1.010) among all partici-
pants (Table 3). Among men, the crude OR was 0.995 (95% CI, 
0.955 to 1.036) and the adjusted OR was 0.987 (95% CI, 0.945 
to 1.031). Among women, the crude OR was 0.989 (95% CI, 
0.967 to 1.013) and the adjusted OR was 0.988 (95% CI, 0.964 
to 1.013).
When we compared individuals with no/mild DED to indi-
viduals with moderate/severe DED, we observed that higher 
serum vitamin D levels were associated with a non-significant 
increase in the risk of moderate/severe DED in the crude anal-
ysis (OR, 1.002; 95% CI, 0.980 to 1.024) and a non-significant 
decrease in the fully adjusted analysis (OR, 0.995; 95% CI, 0.972 
to 1.018). We found a non-significant decrease in the risk of 
moderate/severe DED among men (OR, 0.999; 95% CI, 0.950 
to 1.051) and a non-significant increase in the risk among 
women (OR, 1.003; 95% CI, 0.979 to 1.027) in the crude analy-
sis. These associations remained non-significant after adjust-
ing for all covariates. In the adjusted analysis, the OR among 
women was 0.998 (95% CI, 0.973 to 1.024) (Table 3).
DISCUSSION
The prevalence of DED in the present study was 53.1% 
(42.3% among men and 58.7% among women). When we 
considered only moderate/severe DED, the prevalence was 
30.3% (19.8% among men and 35.7% among women). Previ-
ous studies have revealed that the prevalence of DED has risen 
from 4.3 to 73.5% [5], and our results are within this range. We 
suggest that the diagnosis of mild DED could cause the preva-
lence of DED to be overestimated.
In addition, we observed various gender-related differences 
in the participants’ characteristics, and similar results have 
been observed in a previous study [26]. Some researchers 
have reported findings that may explain the gender-related 
differences, which could be related to differences in sex hor-
mones or sunlight exposure times between men and women 
[26,34]. In the present study, our findings may suggest that 
women are more sensitive to the symptoms of DED. When 
comparing individuals with no DED to those with DED of any 
severity, the protective effect of vitamin D was <1.00, whereas 
this effect was >1.00 when individuals with no/mild DED 
were compared to those with moderate/severe DED. This may 
have been because women were more sensitive to the symp-
toms. When we compared participants with no/mild DED to 
those with moderate/severe DED in the crude analyses, we 
observed opposite directions of the associations of DED with 
elevated serum vitamin D levels among men and women.
The results of some studies have suggested that vitamin D 
levels can affect the immune system, and studies in mice have 
shown that vitamin D enhanced corneal epithelial barrier 
function through tight or gap junctions [12,13,35]. Moreover, 
vitamin D can control ocular surface inflammation by inhibit-
ing Langerhans cell migration and corneal neovascularization 
[36,37]. In humans, researchers have reported that vitamin D 
supplementation is an effective and useful treatment for pa-
tients with DED [38]. Our results suggest that oral vitamin D 
supplementation is less likely to be effective than topical sup-
plementation.
In our study, no association was found between serum vita-
min D levels and DED. One possible explanation for this is that 
it may be difficult for serum vitamin D to reach the cornea be-
cause of its lack of vasculature. Another possibility is a positive 
relationship between aging and serum vitamin D levels. A pre-
vious study reported that the aged in Korea and Thailand had 
higher serum vitamin D levels than the young. They suggested 
that the elderly had more free time for outdoor activities and 
tended to have outdoor jobs, such as being farmers or fisher-
men. Moreover, younger people may use more sunblock than 
the elderly [26,39,40]. 
Previous studies conducted in Korea have evaluated the as-
sociation of serum vitamin D with DED using KNHANES data, 
which were obtained using the participants’ responses to a 
questionnaire (“Have you ever been diagnosed with DED by 
an ophthalmologist?” and “Have you experienced symptoms 
of DED, such as dryness or irritation?”) [28]. However, these 
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studies have reported inconsistent findings, as some research-
ers have defined DED based on an ophthalmological diagno-
sis, while others considered both an ophthalmological diag-
nosis and DED symptoms. For example, Jee et al. [26] reported 
that the risk of DED was lower in higher serum vitamin D quin-
tiles (quintiles 5 vs. 1: OR, 0.85; 95% CI, 0.55 to 1.30; p for 
trend=0.08), although this association was not statistically 
significant. Yoon et al. [25] also reported that low serum vita-
min D levels were a risk factor for DED (OR, 1.158; 95% CI, 1.026 
to 1.308), and Kim et al. [27] reported an elevated crude risk of 
DED at low serum vitamin D levels (OR, 1.61; 95% CI, 1.00 to 
2.61; p=0.04), although this association was attenuated after 
adjusting for covariates (OR, 1.42; 95% CI, 0.84 to 2.40). How-
ever, the rate of DED diagnosis is relatively low, and its preva-
lence could be underestimated if it is based on the ophthal-
mological diagnosis rate, or overestimated if it is based on 
DED symptoms, which are shared with other eye diseases. 
The present study used OSDI scores to identify cases of DED, 
as this tool is valid and reliable for measuring DED symptoms 
and their effects on vision-related quality of life [30,31]. We 
also compared individuals with and without DED, or with no/
mild DED versus moderate/severe DED, because mild symp-
toms may lead to a misclassification of DED. These analyses 
failed to detect a significant association between serum vita-
min D levels and DED, and our findings support previous re-
ports of no significant association between these variables. 
This absence of a significant association may be related to the 
possibility that serum vitamin D levels do not reflect the levels 
in lacrimal fluid. It is also possible that species-based or racial 
differences affect these associations, as previous studies re-
garding the protective effect of vitamin D were conducted in 
mouse models [12,13,35]. 
The present study has some limitations that warrant consid-
eration. First, the cross-sectional design precludes any conclu-
sions regarding causality, although previous studies conduct-
ed in Korea have also used cross-sectional designs. Second, 
our dataset was relatively limited compared to the KNHANES 
data set, which may limit the representativeness of our find-
ings. Nevertheless, our use of the OSDI to detect DED likely 
provided more detailed and objective information regarding 
DED severity. Third, we did not consider seasonal variation in 
serum vitamin D levels. To deal with this variation, previous 
studies using KNHANES data adjusted for sunlight exposure or 
occupation. In the KNHANES, information about sunlight ex-
posure and occupation was acquired through the question-
naire, and the surveys were conducted throughout the year. 
Our data were gathered from October 2014 to January 2015 
and from October 2015 to December 2015. Thus, our data are 
likely to contain less seasonal variation than KNHANES. 
The present study provides epidemiological data regarding 
the absence of an association of serum vitamin D levels and 
DED in the Korean general population. This result is consistent 
with the findings of Jee et al. [26], who analyzed KNHANES 
data. Further studies are needed to investigate the mecha-
nisms and management of DED.
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